Rhenman & Partners Asset Management AB
Long book
$810.5M
Q1 2026
Positions
86
Top-10 weight
32%
concentration
Last quarter
+15.8%
SPY +14.8%
Turnover
29%
of book per quarter
Strategy in plain words
auto-generated from filingsRhenman & Partners Asset Management AB is an institutional manager, specialised in healthcare (83% of the long book), running a $810.5M US long book across 86 positions.
The portfolio is moderately concentrated (top 10 ≈ 32% of the book). The portfolio is actively managed, with meaningful quarterly turnover. Current anchor positions: BOSTON SCIENTIFIC CORP, REGENERON PHARMACEUTICALS, ELI LILLY & CO, INSMED INC, CVS HEALTH CORP.
Over the last 9 quarters its long book ran on average 1.8pp per quarter behind the S&P 500, beating the index in 4 of 9 quarters. Signal value of individual moves is limited — treat changes as weak evidence.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-0.3%
Q2 2024
+7.9%
Q3 2024
-10.3%
Q4 2024
+1.8%
Q1 2025
-1.9%
Q2 2025
+4.2%
Q3 2025
+14.8%
Q4 2025
-7.9%
Q1 2026
+15.8%
Sector allocation
Healthcare 83%
Financials 6%
Consumer discretionary 5%
Technology 4%
Other 3%
Long book by quarter
What does Rhenman & own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| BSX BOSTON SCIENTIFIC CORP | Healthcare | 625.0K | $39.2M | 4.8% | +44.9% |
| REGN REGENERON PHARMACEUTICALS | Healthcare | 48.1K | $37.2M | 4.6% | -21.7% |
| LLY ELI LILLY & CO | Healthcare | 33.7K | $31.0M | 3.8% | -20.1% |
| INSM INSMED INC | Healthcare | 159.8K | $26.1M | 3.2% | +40.7% |
| CVS CVS HEALTH CORP | Healthcare | 336.5K | $24.2M | 3.0% | +0.3% |
| GILD GILEAD SCIENCES INC | Healthcare | 167.8K | $23.4M | 2.9% | +33.0% |
| TMO THERMO FISHER SCIENTIFIC INC | Other | 41.3K | $20.3M | 2.5% | +22.9% |
| BIIB BIOGEN INC | Healthcare | 109.1K | $20.0M | 2.5% | +18.1% |
| VRTX VERTEX PHARMACEUTICALS INC | Healthcare | 43.5K | $19.4M | 2.4% | +26.9% |
| ALHC ALIGNMENT HEALTHCARE INC | Financials | 1.1M | $18.6M | 2.3% | +4.4% |
| ISRG INTUITIVE SURGICAL INC | Healthcare | 36.8K | $17.0M | 2.1% | -23.2% |
| COR CENCORA INC | Consumer discretionary | 52.4K | $16.5M | 2.0% | -17.4% |
| SYK STRYKER CORP | Healthcare | 47.8K | $15.7M | 1.9% | New |
| ABBV ABBVIE INC | Healthcare | 71.6K | $15.6M | 1.9% | -35.3% |
| VEEV VEEVA SYSTEMS INC-CLASS A | Technology | 85.3K | $15.0M | 1.8% | New |
| MCK MCKESSON CORP | Consumer discretionary | 16.9K | $14.6M | 1.8% | -34.2% |
| JAZZ JAZZ PHARMACEUTICALS PLC | Healthcare | 75.9K | $14.3M | 1.8% | +2.5% |
| GH GUARDANT HEALTH INC | Healthcare | 145.0K | $13.4M | 1.7% | +81.3% |
| NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 100.8K | $13.3M | 1.6% | -19.6% |
| EW EDWARDS LIFESCIENCES CORP | Healthcare | 163.0K | $13.1M | 1.6% | -15.8% |
| MDGL MADRIGAL PHARMACEUTICALS INC | Healthcare | 24.1K | $12.6M | 1.6% | +23.0% |
| UNH UNITEDHEALTH GROUP INC | Financials | 45.5K | $12.3M | 1.5% | -17.1% |
| PRCT PROCEPT BIOROBOTICS CORP | Healthcare | 475.0K | $11.9M | 1.5% | -22.3% |
| BMRN BIOMARIN PHARMACEUTICAL INC | Healthcare | 207.0K | $11.7M | 1.4% | -3.7% |
| ABT ABBOTT LABORATORIES | Healthcare | 112.0K | $11.5M | 1.4% | New |
| ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 34.5K | $11.4M | 1.4% | -24.5% |
| RPRX ROYALTY PHARMA PLC- CL A | Healthcare | 233.0K | $11.2M | 1.4% | +12.8% |
| AXSM AXSOME THERAPEUTICS INC | Healthcare | 63.8K | $10.8M | 1.3% | -44.4% |
| NTRA NATERA INC | Healthcare | 51.6K | $10.3M | 1.3% | +27.4% |
| THC TENET HEALTHCARE CORP | Healthcare | 54.0K | $10.2M | 1.3% | -29.4% |
| ADPT ADAPTIVE BIOTECHNOLOGIES | Healthcare | 720.0K | $10.0M | 1.2% | +19.0% |
| LIVN LIVANOVA PLC | Healthcare | 155.0K | $9.9M | 1.2% | -18.4% |
| ELV ELEVANCE HEALTH INC | Financials | 32.3K | $9.5M | 1.2% | +115.3% |
| ARWR ARROWHEAD PHARMACEUTICALS IN | Healthcare | 144.5K | $9.1M | 1.1% | Held |
| GKOS GLAUKOS CORP | Healthcare | 84.0K | $9.0M | 1.1% | -60.0% |
| IQV IQVIA HOLDINGS INC | Healthcare | 53.0K | $9.0M | 1.1% | +100.0% |
| SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 379.3K | $8.9M | 1.1% | -22.1% |
| MIRM MIRUM PHARMACEUTICALS INC | Healthcare | 92.6K | $8.6M | 1.1% | -12.8% |
| IDYA IDEAYA BIOSCIENCES INC | Healthcare | 255.5K | $8.5M | 1.1% | +2.2% |
| PNTG PENNANT GROUP INC/THE | Healthcare | 275.4K | $8.4M | 1.0% | -22.9% |
| NUVL NUVALENT INC-A | Healthcare | 81.2K | $8.3M | 1.0% | -50.3% |
| WAY WAYSTAR HOLDING CORP | Technology | 342.6K | $8.3M | 1.0% | New |
| AVR ANTERIS TECHNOLOGIES GLOBAL | Healthcare | 1.4M | $8.0M | 1.0% | +16.1% |
| MDT MEDTRONIC PLC | Healthcare | 90.0K | $7.8M | 1.0% | -69.6% |
| OSCR OSCAR HEALTH INC - CLASS A | Financials | 660.0K | $7.6M | 0.9% | +153.8% |
| IOVA IOVANCE BIOTHERAPEUTICS INC | Healthcare | 2.1M | $7.2M | 0.9% | +28.8% |
| MLYS MINERALYS THERAPEUTICS INC | Healthcare | 263.1K | $7.1M | 0.9% | +84.5% |
| IONS IONIS PHARMACEUTICALS INC | Healthcare | 92.9K | $7.0M | 0.9% | -41.4% |
| DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 81.6K | $6.9M | 0.8% | -17.2% |
| BBIO BRIDGEBIO PHARMA INC | Healthcare | 90.6K | $6.7M | 0.8% | +11.0% |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 14, 2026 | 86 | $810.5M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 13, 2026 | 94 | $1.07B | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 13, 2025 | 92 | $903.7M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 13, 2025 | 90 | $791.0M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 14, 2025 | 94 | $870.0M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 13, 2025 | 92 | $972.9M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 13, 2024 | 95 | $1.23B | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 13, 2024 | 93 | $1.04B | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 14, 2024 | 84 | $1.06B | canonical | SEC ↗ |